Ozempic for Type 2 Diabetes and Weight Loss: What to Know

What is Ozempic, and what is it approved for?

Ozempic is the brand name for semaglutide as a once-weekly injectable pen. It belongs to the class called GLP-1 receptor agonists — drugs that mimic a gut hormone called glucagon-like peptide-1. The FDA approved Ozempic for the treatment of type 2 diabetes and, importantly, for reducing the risk of major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes and established cardiovascular disease.

Weight loss is a consistent effect of Ozempic, and it is significant — typically more than older diabetes medications — but at the dose approved for diabetes, weight reduction is secondary to blood sugar control. Wegovy is semaglutide at a higher maximum dose (2.4 mg vs. 1 mg for Ozempic), and it is specifically FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition.

How much weight does Ozempic or Wegovy cause?

In the STEP 1 trial — a large randomized controlled study of adults without diabetes using the Wegovy dose — participants lost an average of about 15% of their body weight over approximately 68 weeks on semaglutide 2.4 mg, compared with about 2.4% in the placebo group 1Ref 1Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Average ~15% weight loss with semaglutide 2.4 mg in STEP 1 trial. These are group averages; individual results vary considerably.

A critical finding from follow-up data: most of the weight lost during treatment was regained within about a year after stopping the medication 2Ref 2Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF (2022).Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Most weight regained within ~1 year of stopping semaglutide. This suggests that semaglutide needs to be continued long-term to maintain its effect — a reality worth understanding before starting.

The SELECT trial later showed that semaglutide also reduced major cardiovascular events in people with obesity but without diabetes, adding another evidence-based indication for this class 3Ref 3Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide reduced major cardiovascular events in people with obesity and established cardiovascular disease.

How does Mounjaro (tirzepatide) compare to Ozempic?

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) targets both GLP-1 and GIP receptors — a dual mechanism that appears to amplify the weight-loss effect. In the SURMOUNT-1 trial, people with obesity taking the highest dose of tirzepatide lost an average of about 22% of body weight, more than is typically seen with semaglutide 4Ref 4Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A (2022).Tirzepatide Once Weekly for the Treatment of Obesity.Average ~22% weight loss with highest dose of tirzepatide in SURMOUNT-1 trial.

For blood sugar control in type 2 diabetes, tirzepatide also showed strong A1c reductions in its clinical program. FDA-approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Key comparisons at a glance: | | Ozempic | Wegovy | Mounjaro / Zepbound | |---|---|---|---| | Drug | Semaglutide | Semaglutide | Tirzepatide | | Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP dual | | FDA approval | Type 2 diabetes, CV risk | Obesity / overweight | Diabetes / obesity | | Frequency | Once weekly injection | Once weekly injection | Once weekly injection | | Average weight loss (trials) | ~15% (Wegovy dose) | ~15% | ~22% (highest dose) |

Neither is universally "better" — the right choice depends on primary goal (blood sugar vs. weight), cost, insurance coverage, and individual response.

What are the common side effects?

Both semaglutide and tirzepatide share a similar side effect profile because they work on the same pathway:

• Nausea, vomiting, diarrhea, and constipation are the most common, especially when starting or increasing the dose
• These usually improve over weeks as the body adjusts
• Taking medication with food, eating smaller meals, and going slowly with dose increases all help manage GI symptoms
• Rare but serious: both medications carry a warning about thyroid C-cell tumors based on animal studies (the clinical significance in humans is uncertain, but they are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome)
• Pancreatitis is a rare concern — persistent severe abdominal pain should prompt urgent care

Does insurance cover Ozempic or Mounjaro?

Coverage varies substantially. Ozempic and Mounjaro are more commonly covered for type 2 diabetes with prior authorization. Wegovy and Zepbound — the weight-management branded versions — have more variable coverage; many commercial plans and most state Medicaid programs have historically limited or excluded obesity medications, though coverage is expanding.

A Gale primary care clinician can help you document a diabetes or weight-related diagnosis, write the prescription, and work through prior authorization requirements. Out-of-pocket costs without insurance are significant, so understanding coverage upfront matters.